NeuroCatch Inc., a brain health technology company based out of British Columbia, announced today it will open its United States headquarters in Greater Phoenix at the Phoenix Bioscience Core (PBC).
MORE NEWS: Phoenix bucket list: 25 things you must do
INDUSTRY INSIGHTS: Want more news like this? Get our free newsletter here
The company, an alumnus of the 2025 Arizona State University (ASU)/Mayo Clinic MedTech Accelerator, will support commercialization, manufacturing, sales, distribution, and clinical trials out of its new 1,000-square-foot office space. Operations began Oct. 1, with further scaling of operations planned into 2026.
“Phoenix has built one of the most dynamic healthcare and innovation ecosystems in the world, fueled with passionate people across all spectrums, and we are excited to become a part of it for the U.S. and global commercialization of our product,” CEO Derek Norsworthy said. “With NeuroCatch, we look forward to contributing our own breakthrough in brain health, helping expand the Valley’s impact outward to communities across the nation and around the world.”
This location represents NeuroCatch’s first major U.S. presence and will serve as a launchpad for commercialization throughout the U.S. Its primary technology, the NeuroCatch Platform, provides objective, rapid and non-invasive cognitive assessments using electroencephalography (EEG)-based brain vital signs. The company intends to hire approximately 10 new employees over the first three years.
“NeuroCatch chose Phoenix because this is where bold ideas in medicine become real-world breakthroughs,” Phoenix Mayor Kate Gallego said. “Their expansion to the Phoenix Bioscience Core strengthens our growing ecosystem of researchers, clinicians, and entrepreneurs who are redefining what’s possible in neurotechnology. Phoenix is proud to be a place where innovation thrives and the future of healthcare is being built every day.”
Phoenix’s bioscience and medtech sectors have emerged as one of the most rapidly growing ecosystems in the nation, backed by a workforce that grew more than 50% from 2018-23 and a growing number of clusters in the region. The PBC is a major hub of bioscience activity, serving as a premier environment for research activities over a 30-acre medical and bioscience campus with a collection of Arizona’s three major universities, three major hospital systems and a mixture of public and private research.
“The blend of Greater Phoenix’s renowned healthcare ecosystem, opportunities for innovators and entrepreneurs, and growing talent pool made it the ideal region for NeuroCatch’s national headquarters,” said Greater Phoenix Economic Council Vice President of Business Development Allison Bakovic. “Surrounded by partners in PBC, NeuroCatch will be able to maximize its efforts to advance and commercialize its neurotechnology around the nation.”
About NeuroCatch
NeuroCatch Inc. is a leader in advanced brain health technology with its flagship product, the NeuroCatch ® Platform, is a medical device that provides objective, rapid, and non-invasive cognitive assessments using EEG-based Brain Vital Signs. Recognized globally as a breakthrough in neurotechnology, NeuroCatch is trusted by clinicians, researchers, sports organizations, and military programs to better understand, monitor, and optimize brain health.
